Do Kim
Stock Analyst at Piper Sandler
(2.03)
# 3,068
Out of 5,050 analysts
92
Total ratings
44.93%
Success rate
3.01%
Average return
Main Sectors:
Stocks Rated by Do Kim
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| IONS Ionis Pharmaceuticals | Maintains: Overweight | $62 → $63 | $73.55 | -14.34% | 18 | Feb 22, 2024 | |
| TVTX Travere Therapeutics | Maintains: Overweight | $42 → $46 | $32.34 | +42.24% | 6 | Feb 21, 2023 | |
| VRTX Vertex Pharmaceuticals | Maintains: Neutral | $296 | $409.47 | -27.71% | 13 | Feb 8, 2023 | |
| GILD Gilead Sciences | Maintains: Overweight | $111 → $112 | $118.84 | -5.76% | 7 | Feb 3, 2023 | |
| SDGR Schrödinger | Maintains: Overweight | $86 → $87 | $17.78 | +389.31% | 5 | Jan 19, 2023 | |
| CDXS Codexis | Maintains: Overweight | $22 → $23 | $1.69 | +1,260.95% | 2 | Jan 19, 2023 | |
| RIGL Rigel Pharmaceuticals | Maintains: Neutral | $10 → $20 | $35.19 | -43.17% | 3 | Aug 17, 2022 | |
| REPL Replimune Group | Maintains: Overweight | $44 → $43 | $8.31 | +417.45% | 2 | Aug 16, 2022 | |
| EXEL Exelixis | Maintains: Overweight | $30 → $32 | $40.81 | -21.59% | 1 | Jul 26, 2022 | |
| ABCL AbCellera Biologics | Maintains: Overweight | $21 → $22 | $3.91 | +462.66% | 4 | Jul 26, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $28 → $19 | $28.95 | -34.37% | 3 | Jun 23, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $16 | $4.73 | +238.27% | 1 | Mar 8, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $185 | $442.70 | -58.21% | 14 | Jan 25, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $900 | $3.96 | +22,627.27% | 1 | Dec 18, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $27 → $35 | $68.24 | -48.71% | 11 | May 12, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $7 → $20 | $1.07 | +1,769.16% | 1 | Mar 6, 2018 |
Ionis Pharmaceuticals
Feb 22, 2024
Maintains: Overweight
Price Target: $62 → $63
Current: $73.55
Upside: -14.34%
Travere Therapeutics
Feb 21, 2023
Maintains: Overweight
Price Target: $42 → $46
Current: $32.34
Upside: +42.24%
Vertex Pharmaceuticals
Feb 8, 2023
Maintains: Neutral
Price Target: $296
Current: $409.47
Upside: -27.71%
Gilead Sciences
Feb 3, 2023
Maintains: Overweight
Price Target: $111 → $112
Current: $118.84
Upside: -5.76%
Schrödinger
Jan 19, 2023
Maintains: Overweight
Price Target: $86 → $87
Current: $17.78
Upside: +389.31%
Codexis
Jan 19, 2023
Maintains: Overweight
Price Target: $22 → $23
Current: $1.69
Upside: +1,260.95%
Rigel Pharmaceuticals
Aug 17, 2022
Maintains: Neutral
Price Target: $10 → $20
Current: $35.19
Upside: -43.17%
Replimune Group
Aug 16, 2022
Maintains: Overweight
Price Target: $44 → $43
Current: $8.31
Upside: +417.45%
Exelixis
Jul 26, 2022
Maintains: Overweight
Price Target: $30 → $32
Current: $40.81
Upside: -21.59%
AbCellera Biologics
Jul 26, 2022
Maintains: Overweight
Price Target: $21 → $22
Current: $3.91
Upside: +462.66%
Jun 23, 2022
Maintains: Overweight
Price Target: $28 → $19
Current: $28.95
Upside: -34.37%
Mar 8, 2021
Initiates: Outperform
Price Target: $16
Current: $4.73
Upside: +238.27%
Jan 25, 2021
Downgrades: Market Perform
Price Target: $185
Current: $442.70
Upside: -58.21%
Dec 18, 2020
Initiates: Outperform
Price Target: $900
Current: $3.96
Upside: +22,627.27%
May 12, 2020
Maintains: Outperform
Price Target: $27 → $35
Current: $68.24
Upside: -48.71%
Mar 6, 2018
Maintains: Outperform
Price Target: $7 → $20
Current: $1.07
Upside: +1,769.16%